- Home
- PRGO vs ADPT Comparison
PRGO vs ADPT Comparison
Compare PRGO & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRGO
- ADPT
- Stock Information
- Founded
- PRGO 1887
- ADPT 2009
- Country
- PRGO Ireland
- ADPT United States
- Employees
- PRGO N/A
- ADPT N/A
- Industry
- PRGO Biotechnology: Pharmaceutical Preparations
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PRGO Health Care
- ADPT Health Care
- Exchange
- PRGO Nasdaq
- ADPT Nasdaq
- Market Cap
- PRGO 3.1B
- ADPT 2.6B
- IPO Year
- PRGO 1991
- ADPT 2019
- Fundamental
- Price
- PRGO $14.41
- ADPT $14.94
- Analyst Decision
- PRGO Buy
- ADPT Strong Buy
- Analyst Count
- PRGO 4
- ADPT 10
- Target Price
- PRGO $22.50
- ADPT $15.90
- AVG Volume (30 Days)
- PRGO 2.8M
- ADPT 1.7M
- Earning Date
- PRGO 11-05-2025
- ADPT 11-05-2025
- Dividend Yield
- PRGO 8.03%
- ADPT N/A
- EPS Growth
- PRGO N/A
- ADPT N/A
- EPS
- PRGO N/A
- ADPT N/A
- Revenue
- PRGO $4,281,800,000.00
- ADPT $252,754,000.00
- Revenue This Year
- PRGO $2.12
- ADPT $36.43
- Revenue Next Year
- PRGO $0.49
- ADPT $12.31
- P/E Ratio
- PRGO N/A
- ADPT N/A
- Revenue Growth
- PRGO N/A
- ADPT 42.57
- 52 Week Low
- PRGO $14.18
- ADPT $4.27
- 52 Week High
- PRGO $30.93
- ADPT $17.89
- Technical
- Relative Strength Index (RSI)
- PRGO 12.76
- ADPT 42.01
- Support Level
- PRGO $21.14
- ADPT $16.51
- Resistance Level
- PRGO $22.01
- ADPT $17.75
- Average True Range (ATR)
- PRGO 0.72
- ADPT 0.86
- MACD
- PRGO -0.74
- ADPT -0.31
- Stochastic Oscillator
- PRGO 3.06
- ADPT 12.22
About PRGO Perrigo Company plc
Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).